<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468699</url>
  </required_header>
  <id_info>
    <org_study_id>VinmecRISCGT78</org_study_id>
    <nct_id>NCT03468699</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia</brief_title>
  <official_title>Outcomes of Autologous Bone Marrow Mononuclear Stem Cell (BMMC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia After Kasai's Operation: An Open Label Uncontrolled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow
      mononuclear stem cell transplantation for Children Suffering from Liver Cirrhosis Due to
      Biliary Atresia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is ferformed to evaluate the safety and effectiveness of autologous bone marrow
      mononuclear stem cell transplantation in the management of Liver Cirrhosis Due to Biliary
      Atresia after Kasai's operation of 20 patients at Vinmec Research Institute of Stem Cell and
      Gene Technology, Hanoi, Vietnam from January 2017 to December 2018
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the changes in cholestasis</measure>
    <time_frame>Baseline, 3, 6 months and 12 months after transplantation</time_frame>
    <description>Using Bilirubin (total, direct and indirect) to measure the changes in cholestasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the changes in Liver function</measure>
    <time_frame>Baseline, 3, 6 months and 12 months after transplantation</time_frame>
    <description>Using AST (Aspart transaminase) and ALT (Alanin transaminase) (units: U/L), GGT (Gamma GT) (units: UI/L), and Bilirubin (units: mg/dL) to measure the changes in Liver function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the changes in level of cirrhosis</measure>
    <time_frame>Baseline, 3, 6 months and 12 months after transplantation</time_frame>
    <description>Using PELD score (according to the suggestion of The Liver and Intestinal Organ Transplantation Committee in 2009). PELD is calculated based on three indicators: albumin (g / dL), bilirubin (units: mg / dL) and INR (international normalized ratio). Formula: PELD = 10 * (0.48 * ln(Serum Bilirubin) + 1.857 * ln(INR) - 0.687 * ln(Albumin) + (0.436 if patient is less than 1 year old) + (0.667 if patient has growth failure)). Evaluate the result:
If PELD &lt;10: good results
If 10 &lt;PELD &lt;15: average results
If PELD&gt; 15: bad results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the changes in liver biopsy</measure>
    <time_frame>Baseline, 3, 6 months and 12 months after transplantation</time_frame>
    <description>Liver biopsy, in combination with history and physical examination data, is a powerful clinical tool for diagnosing and treating liver disease to evaluate the changes in liver biopsy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cirrhosis, Biliary</condition>
  <arm_group>
    <arm_group_label>Autologous BMMC transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Autologous BMMC transplantation</intervention_name>
    <description>Stem cell transplantation</description>
    <arm_group_label>Autologous BMMC transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children were diagnosed with Liver Cirrhosis Due to biliary atresia after Kasai's
             operation

          -  1 year old or older

          -  Patients with manifestation of cirrhosis after Kasai's operation: hepatomegaly,
             congestive splenomegaly, elevated liver enzymes, Esophageal Varices (based on
             Endoscopic Diagnosis), cirrhosis (based on liver biopsy)

        Exclusion Criteria:

          -  Under 1 year old patients

          -  Epilepsy

          -  Coagulation disorders

          -  Allergy to anesthetic agents

          -  Severe health conditions such as cancer, failure of heart, lung, liver or kidney

          -  Active infections

          -  Severe psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liem Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinmec Research Institute of Stem Cell and Gene Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liem Nguyen, PhD, MD</last_name>
    <phone>986565015</phone>
    <email>v.liemnt@vinmec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vinmec Research Institute of Stem Cell and Gene Technology</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liem T Nguyen, MD., PhD</last_name>
      <phone>(+844)39743556</phone>
      <phone_ext>1420</phone_ext>
      <email>v.liemnt@vinmec.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinmec Research Institute of Stem Cell and Gene Technology</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Nguyen, MPH</last_name>
      <phone>(+84)914740683</phone>
      <email>hoangphuonghsph@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liem Nguyen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Nicolas C, Wang Y, Luebke-Wheeler J, Nyberg SL. Stem Cell Therapies for Treatment of Liver Disease. Biomedicines. 2016 Jan 6;4(1). pii: E2. doi: 10.3390/biomedicines4010002. Review.</citation>
    <PMID>28536370</PMID>
  </reference>
  <reference>
    <citation>Levicar N, Dimarakis I, Flores C, Tracey J, Gordon MY, Habib NA. Stem cells as a treatment for chronic liver disease and diabetes. Handb Exp Pharmacol. 2007;(180):243-62. Review.</citation>
    <PMID>17554512</PMID>
  </reference>
  <reference>
    <citation>Irfan A, Ahmed I. Could Stem Cell Therapy be the Cure in Liver Cirrhosis? J Clin Exp Hepatol. 2015 Jun;5(2):142-6. doi: 10.1016/j.jceh.2014.03.042. Epub 2014 Mar 27. Review.</citation>
    <PMID>26155042</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Kumar L, Mohanty S, Kumar R, Datta Gupta S, Gupta DK. Bone marrow mononuclear stem cell infusion improves biochemical parameters and scintigraphy in infants with biliary atresia. Pediatr Surg Int. 2011 Jan;27(1):81-9. doi: 10.1007/s00383-010-2712-4.</citation>
    <PMID>20857300</PMID>
  </reference>
  <reference>
    <citation>Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao P, Pande G, Narusu ML, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report. Transplant Proc. 2008 May;40(4):1153-5. doi: 10.1016/j.transproceed.2008.03.110.</citation>
    <PMID>18555137</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous bone marrow Transplantation</keyword>
  <keyword>biliary atresia</keyword>
  <keyword>Kasai's operation</keyword>
  <keyword>liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Biliary Atresia</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

